Exploratory study of NS 065/NCNP 01 in Duchenne muscular dystrophy
Phase of Trial: Phase I
Latest Information Update: 11 Jan 2018
At a glance
- Drugs NS 065 (Primary)
- Indications Duchenne muscular dystrophy
- Focus Adverse reactions
- 10 Jun 2017 Biomarkers information updated
- 23 Mar 2015 Status changed from active, no longer recruiting to completed, as reported in a Nippon Shinyaku media release.
- 04 Sep 2014 Planned End Date changed from 1 Nov 2014 to 1 Mar 2015 as reported by ClinicalTrials.gov.